WOBURN, Mass.--(BUSINESS WIRE)--
ArQule, Inc. (NASDAQ: ARQL) today announced that it will report its
financial results for the fiscal 2013 year-end and fourth quarter on
Wednesday, March 5, 2014 at 7:00 a.m. eastern time. The Company will
hold a conference call at 9:00 a.m. eastern time that day to discuss
Conference Call and Webcast
||Wednesday, March 5, 2014|
||9:00 a.m., Eastern Time|
Conference Call Numbers
Domestic (toll free):
A replay of the conference call will be available beginning on March 5,
two hours after the call’s completion for seven days and can be
accessed by dialing toll-free (855) 859-2056 or (800) 585-8367 and
outside the U.S. (404) 537-3406. The confirmation code for replayed
calls is 31423627.
is a biotechnology company engaged in the research and
development of next-generation, small-molecule cancer therapeutics. The
Company’s targeted, broad-spectrum products and research programs are
focused on key biological processes that are central to human cancers.
ArQule’s lead product, in Phase 2 and Phase 3 clinical development, is
tivantinib (ARQ 197), an oral, selective inhibitor of the c-MET receptor
tyrosine kinase. The Company’s pipeline includes: ARQ 092, designed to
inhibit the AKT serine/threonine kinase, and ARQ 087, designed to
inhibit fibroblast growth factor receptor (FGFR). ArQule’s current
discovery efforts, which are based on the ArQule Kinase Inhibitor
Platform (AKIP™), are focused on the identification of novel kinase
inhibitors that are potent, selective and do not compete with ATP
(adenosine triphosphate) for binding to the kinase.
ArQule, Inc.William B. Boni
Source: ArQule, Inc.